When the efficacy of adjuvant therapy (including anti-PD-1 agents and BRAF/MEK inhibitors) was analyzed in a Japanese study, the 3-year time-to-relapse (TTR) was significantly worse in AM patients compared to non-acral CM patients following adjuvant therapy (HR 0.56; 95% CI: 0.34–0.92; p = 0.021) [109]. The gene discussed is BRAF; the disease is acute myeloblastic leukemia with maturation.